Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san diego blog main
9
×
san diego top stories
fda
national top stories
biotech
boston blog main
boston top stories
new york blog main
clinical trials
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
san diego
boston
boston scientific
bristol-myers squibb
cancer
deals
drugs
eli lilly
immunotherapy
investing
loxo oncology
What
time
9
×
fda
approved
days
drug
friday
gone
heart
medicine
patients
real
startup
acquire
acutus
add
adding
adds
agency
ago
aimmune
airport
allergy
alliance
alnylam
annual
apocalypse
apparent
approval
approve
atrial
awaits
awarded
awarepoint
beds
bio
biological
board
boston
bristol
business
Language
unset
Current search:
time
×
" san diego blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Acutus, Maker of Next-Gen Electrophysiology Tech, Adds $100M Series D
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
5 years ago
No Vital Signs Apparent at Wireless Health Specialist Awarepoint